MDCO News and Press, The Medicines Company From 08/26/19

­ ORION-11 study met all primary and secondary efficacy endpoints with efficacy consistent with Phase 1 and 2 studies ­ Safety profile of inclisiran was at least as favorable as in ORION-1 Phase 2 and ORION-3 open-label extension studies ­ Detailed data will be presented...

In terms of controlling what they can control, I believe Alnylam Pharmaceuticals ( ALNY ) management is doing a good job. While there has certainly been criticism of the high cash burn and the large sums that the company spends on R&D, I believe funding a robust Phase III development pro...

This article is part of a series that provides an ongoing analysis of the changes made to David Einhorn's Greenlight Capital 13F portfolio on a quarterly basis. It is based on Einhorn's regulatory 13F Form filed on 08/14/2019. Please visit our Tracking David Einhorn's Greenlight Capital Hol...

Paratek Pharmaceuticals ( PRTK ) reported earnings on Tuesday, August 6, with the stock trading up over 30% in response to the report and then running further throughout the rest of the week. I find the numbers from the launch of Nuzyra (omadacycline), however, to be less than encouraging. I...

Regeneron Pharmaceuticals (NASDAQ: REGN ) announces the successful outcome of a Phase 3 clinical trial, ELIPSE HoFH , evaluating evinacumab in patients with an inherited form of severely elevated levels of "bad" (LDL-C) cholesterol called homozygous familial hypercholesterolemia (HoFH). ...

I took interest in The Medicines Company ( MDCO ) as part of my research on Alnylam ( ALNY ), a potential Long-Term Growth Portfolio holding which has an economic interest in MDCO’s main asset inclisiran. The company is about to report inclisiran’s phase 3 topline results...

The Medicines Company (MDCO) Q2 2019 Earnings Conference Call July 24, 2019 08:30 AM ET Company Participants Krishna Gorti - Vice President, Investor Relations Mark Timney - Chief Executive Officer Christopher Visioli - Chief Financial Officer Peter Wijngaard - Chief Developmen...

- Sequential release of topline pivotal Phase 3 data readouts expected to start in second half of the third quarter - Independent Data Monitoring Committee recommends continuation of inclisiran Phase 3 clinical trials after seventh un-blinded data review - ORION-11 data expected ...

Biotech Pulse The first half of 2019 had a little bit of everything for biotechs. After a punishing close to last year, with the Nasdaq Biotechnology Index ( IBB ) down 10% for 2018, biotechs rebounded during the first quarter along with the broader market. However, the second quarter provid...

The Medicines Company (NASDAQ: MDCO) will host a conference call and audio webcast on Wednesday, July 24, 2019 at 8:30 a.m. EDT to discuss its second quarter 2019 financial results and operational developments. The conference call may be accessed by telephone as follows: A live audio ...